tamoxifen
Showing 1 - 25 of 142
Duchenne Muscular Dystrophy Trial (Tamoxifen)
Completed
- Duchenne Muscular Dystrophy
- Tamoxifen
- (no location specified)
Jul 21, 2022
Glioblastoma Multiforme Trial in Edmonton (Tamoxifen, Etoposide)
Recruiting
- Glioblastoma Multiforme
- Tamoxifen
- Etoposide
-
Edmonton, Alberta, CanadaCross Cancer Institute
Mar 28, 2022
Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension Trial in Nashville (Tamoxifen, Placebo
Recruiting
- Hypertension
- +8 more
- Tamoxifen
- Placebo Oral Tablet
-
Nashville, TennesseeVanderbilt University Medical Center
Mar 28, 2022
Infertility Trial in San Francisco (Tamoxifen, Letrozole)
Recruiting
- Infertility
- Tamoxifen
- Letrozole
-
San Francisco, CaliforniaUniversity of California at San Francisco
Apr 29, 2022
Breast Cancer, Breast Cancer, Early-Onset Trial (Giredestrant, Tamoxifen)
Not yet recruiting
- Breast Cancer
- Breast Cancer, Early-Onset
- Giredestrant
- Tamoxifen
- (no location specified)
Dec 12, 2022
Vulvar Atrophy Trial in Adelaide, Nedlands (Tamoxifen, Placebo)
Recruiting
- Vulvar Atrophy
- Tamoxifen
- Placebo
-
Adelaide, Southern Australia, Australia
- +1 more
May 12, 2022
Estrogen Receptor Positive Breast Cancer Trial in Houston, Sugar Land (TAK-228, Tamoxifen)
Completed
- Estrogen Receptor Positive Breast Cancer
- TAK-228
- Tamoxifen
-
Houston, Texas
- +2 more
Aug 27, 2021
Breast Cancer Trial in Milan (Tamoxifen, Placebo)
Active, not recruiting
- Breast Cancer
- Tamoxifen
- Placebo
-
Milan, ItalyEuropean Institute of Oncology
Aug 12, 2021
Ovarian Cancer Trial in Sydney (SUBA-itraconazole, Tamoxifen)
Not yet recruiting
- Ovarian Cancer
- SUBA-itraconazole
- Tamoxifen
-
Sydney, New South Wales, AustraliaKinghorn Cancer Centre, St. Vincent's Hospital
Dec 13, 2021
Atypical Hyperplasia, Lobular Carcinoma in Situ Trial in Rochester (Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 2 mg/each
Recruiting
- Atypical Hyperplasia
- Lobular Carcinoma in Situ
- Tamoxifen
- +2 more
-
Rochester, MinnesotaMayo Clinic
Sep 13, 2021
Breast Cancer Trial in Singapore (Tamoxifen)
Recruiting
- Breast Cancer
- Tamoxifen
-
Singapore, SingaporeNational Cancer Centre
Jul 5, 2021
Breast Cancer Female Trial (All trans-retinoic acid, 13-Cis Retinoic Acid plus Tocopherol, Mifepristone)
Not yet recruiting
- Breast Cancer Female
- All trans-retinoic acid
- +6 more
- (no location specified)
Aug 17, 2021
Breast Cancer, Breast Cancer - Female, Breast Cancer - Male Trial in Tampa (Tamoxifen, Ribociclib, Goserelin)
Completed
- Breast Cancer
- +2 more
- Tamoxifen
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jan 13, 2022
Metastatic Breast Cancer, Hormone Receptor Positive Trial in United States (Palbociclib, Tamoxifen, Fulvestrant)
Completed
- Metastatic Breast Cancer
- Hormone Receptor Positive
- Palbociclib
- +2 more
-
San Francisco, California
- +8 more
Feb 16, 2022
Metastatic Breast Cancer Trial in Pittsburgh (Fulvestrant, Tamoxifen, Palbociclib)
Active, not recruiting
- Metastatic Breast Cancer
- Fulvestrant
- +2 more
-
Pittsburgh, PennsylvaniaMagee-Womens Hospital UPMC
Jul 22, 2021
Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)
Recruiting
- Breast Cancer
- +3 more
- Infigratinib
- +3 more
-
Stanford, CaliforniaStanford University
Feb 16, 2022
Non Metastatic Breast Cancer Trial in Lyon, Paris, Saint Herblain (tamoxifen)
Completed
- Non Metastatic Breast Cancer
- tamoxifen
-
Lyon, France
- +2 more
Mar 10, 2021
Breast Tumors Trial in Worldwide (Palbociclib, Placebo, Tamoxifen)
Active, not recruiting
- Breast Neoplasms
- Palbociclib
- +3 more
-
Nagoya, Aichi, Japan
- +22 more
Apr 4, 2022
Breast Cancer Trial in Jakarta (Tamoxifen)
Active, not recruiting
- Breast Cancer
- Tamoxifen
-
Jakarta, DKI Jakarta, IndonesiaMRCCC Siloam Hospitals Semanggi
Aug 12, 2022
Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma Trial in Boston
Not yet recruiting
- Male Breast Cancer
- +2 more
- Tamoxifen
- +3 more
-
Boston, Massachusetts
- +1 more
Aug 12, 2022
ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer Trial (Elacestrant, Tamoxifen, Letrozole 2.5mg)
Not yet recruiting
- ER-positive Breast Cancer
- +3 more
- Elacestrant
- +4 more
- (no location specified)
Aug 22, 2022